Organogenesis Launches PuraPly Wound Management Products

July 23, 2015

Organogenesis Inc. launched its new PuraPly™ wound management products, including PuraPly Antimicrobial (PuraPly AM), the first FDA-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent.

PuraPly and PuraPly AM are the latest additions to the Organogenesis portfolio of advanced wound-care products. Both products are FDA 510(k)-cleared Class II medical devices approved for acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.

When used within the first four weeks of treatment, PuraPly creates an optimal environment for wounds of varying depth, regardless of severity or duration. PuraPly comprises layers of inherently strong, purified and biocompatible natural collagen matrix.  PuraPly AM is unique in that it combines purified collagen with PHMB which provides broad antimicrobial coverage, protecting against a wide range of bacteria that colonize wounds and can progress to biofilm formation and infection.  PuraPly AM can reduce the bacterial load in the wound bed, which if not addressed, can negatively impact tissue repair and delay healing.

“Organogenesis is excited to be advancing healing through new wound care technologies that serve unmet needs and are available across the spectrum of wound management and healing applications,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis Inc. “With the addition of the PuraPly wound management products to our portfolio, we now offer clinicians products to treat wounds immediately when they enter their wound centers.  Importantly, with PuraPly Antimicrobial, physicians have a treatment option for wounds with a high degree of bioburden. The PuraPly products can be used on most wounds that clinicians see in their centers.  For diabetic ulcer and venous leg ulcer wounds that are truly chronic and do not respond to wound management, Organogenesis offers our Apligraf and Dermagraft bioengineered living cell-based products, the only FDA-approved wound healing therapies in the ‘skin substitute’ class.”

PuraPly AM and PuraPly are both available in a range of sizes, in order to meet the needs of a variety of wound types. Both have been approved for pass-through reimbursement in the hospital outpatient setting by the Centers for Medicare and Medicaid Services.


Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free